Search research articles
Contact Us
Filters
Showing results (121-130 of 171) with videos related to
Page
of 18
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
April 26, 2021
Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas
Christoph Schliemann, Teresa Hemmerle, Andrew F Berdel, et al.
Cancer Letters
|
August 3, 2020
Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model
Jun Yamamoto, Kentaro Miyake, Qinghong Han, et al.
Cancer Chemotherapy and Pharmacology
|
October 27, 2020
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis
Salvador Fudio, Josep Tabernero, Vivek Subbiah, et al.
Cancers
|
February 11, 2023
SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma
Erlinda Maria Gordon, Sant P Chawla, Walter Andree Tellez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2003
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group
Paul J Hesketh, Steven M Grunberg, Richard J Gralla, et al.
Future Oncology (London, England)
|
August 30, 2022
A phase II study of TAS-117 in patients with advanced solid tumors harboring germline <i>PTEN</i>-inactivating mutations
Jordi Rodón, Pauline Funchain, Theodore W Laetsch, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 12, 2025
A first-in-human, Phase 1/2a, open-label study of SQ3370, a first-in-class doxorubicin-based click chemistry therapeutic, in patients with advanced solid tumors
S P Chawla, E Abella, S Wieland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 29, 2022
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
Vivek Subbiah, Irene Braña, Alessandra Longhi, et al.
Anticancer Research
|
September 15, 2019
Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma
Takashi Higuchi, Hiromichi Oshiro, Kentaro Miyake, et al.
Cancer Chemotherapy and Pharmacology
|
February 14, 2019
Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model
Kentaro Miyake, Tasuku Kiyuna, Kei Kawaguchi, et al.
Page
of 18
Search research articles
Search
Showing results (121-130 of 171) with videos related to
Sort By:
Page
of 18
European Journal of Cancer (Oxford, England : 1990)
|
April 26, 2021
Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas
Christoph Schliemann, Teresa Hemmerle, Andrew F Berdel, et al.
Cancer Letters
|
August 3, 2020
Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model
Jun Yamamoto, Kentaro Miyake, Qinghong Han, et al.
Cancer Chemotherapy and Pharmacology
|
October 27, 2020
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis
Salvador Fudio, Josep Tabernero, Vivek Subbiah, et al.
Cancers
|
February 11, 2023
SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma
Erlinda Maria Gordon, Sant P Chawla, Walter Andree Tellez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2003
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group
Paul J Hesketh, Steven M Grunberg, Richard J Gralla, et al.
Future Oncology (London, England)
|
August 30, 2022
A phase II study of TAS-117 in patients with advanced solid tumors harboring germline <i>PTEN</i>-inactivating mutations
Jordi Rodón, Pauline Funchain, Theodore W Laetsch, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 12, 2025
A first-in-human, Phase 1/2a, open-label study of SQ3370, a first-in-class doxorubicin-based click chemistry therapeutic, in patients with advanced solid tumors
S P Chawla, E Abella, S Wieland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 29, 2022
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
Vivek Subbiah, Irene Braña, Alessandra Longhi, et al.
Anticancer Research
|
September 15, 2019
Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma
Takashi Higuchi, Hiromichi Oshiro, Kentaro Miyake, et al.
Cancer Chemotherapy and Pharmacology
|
February 14, 2019
Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model
Kentaro Miyake, Tasuku Kiyuna, Kei Kawaguchi, et al.
Page
of 18